


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Mitsuo Nishikawa) I hereby certify that this correspondence is
Serial No: To be assigned) being deposited with the U.S. Postal Service as
Filed: Herewith (October 21, 2004)) Express Mail, Airbill No. EV 233 439 824 US
Title: Polypeptide Having an Activity to) in an envelope addressed to: Mail Stop PCT,
Support Proliferation or Survival of) Commissioner for Patents, P.O. Box 1450
Hematopoietic Stem Cell or Hematopoietic) Alexandria, VA 22313-1450, on this date:
Progenitor Cell, and DNA Coding for the Same)
Group Art Unit: To be assigned) October 21, 2004
Examiner: To be assigned)
This application is filed as a U.S. National)
Phase under 35 U.S.C. 371 of International)
Patent Application No. PCT/JP03/05383,)
which was filed April 25, 2003.)

Richard Zimmermann

STATEMENT UNDER 37 C.F.R. §§1.821(f)

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

I hereby state that the content of the paper and computer readable copy of the Sequence Listing, submitted herewith in accordance with 37 C.F.R. §§ 1.821 and 1.825, are the same and include no new matter.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN LLP
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6357

By:


Sharon M. Sintich, Ph.D.
Registration No. 48,484
Attorney for Applicants

October 21, 2004